Literature DB >> 6461061

Degradation of amyloid proteins by different serine proteases.

B Skogen, J B Natvig.   

Abstract

A protein extract was obtained from normal human serum by adsorption to unsubstituted Sepharose 4B. This extract contained one or several enzymes with SAA and AA degrading capacity. The optimal pH for degradation of SAA was about 7.3. On fractionation of the enzyme extract on Sephadex G-160, the active component was eluted in the V0 peak. The V0 fraction, which on double immunodiffusion analysis was found to contain alpha 2-macroglobulin, was also active against synthetic substrates used to determine the activity of thrombin and plasma kallikrein. Gel filtration under dissociating conditions and molecular weight estimation further indicated the presence of those enzymes in the preparation. Several serine proteases which are known to be inhibited by alpha 2-macroglobulin possessed AA and SAA degrading activity. On degradation of SAA, an intermediate split product with molecular weight similar to AA was formed. Kallikrein, plasmin and elastase were also able to degrade intact amyloid fibrils suspended in phosphate-buffered saline.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6461061     DOI: 10.1111/j.1365-3083.1981.tb00579.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

Review 1.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

2.  Development of quantitative mass spectrometric immunoassay for serum amyloid A.

Authors:  Olgica Trenchevska; Hussein N Yassine; Chad R Borges; Randall W Nelson; Dobrin Nedelkov
Journal:  Biomarkers       Date:  2016-07-22       Impact factor: 2.658

3.  Biochemical nature and cellular origin of amyloid enhancing factor (AEF) as determined by anti-AEF antibody.

Authors:  K Alizadeh-Khiavi; Z Ali-Khan
Journal:  Br J Exp Pathol       Date:  1988-10

4.  Pathogenesis of secondary amyloidosis in an alveolar hydatid cyst-mouse model: histopathology and immuno/enzyme-histochemical analysis of splenic marginal zone cells during amyloidogenesis.

Authors:  T Du; Z Ali-Khan
Journal:  J Exp Pathol (Oxford)       Date:  1990-06

5.  Activities of lysosomal enzymes and levels of serum amyloid A (SAA) in blood plasma of hamsters during casein induction of AA-amyloidosis.

Authors:  P R Hol; A M van Ederen; F W Snel; J P Langeveld; J H Veerkamp; E Gruys
Journal:  Br J Exp Pathol       Date:  1985-06

6.  Alveolar hydatid cyst induced amyloid enhancing factor (AEF): physicochemical properties and abolition of AEF activity by serine protease inhibitors.

Authors:  G V Abankwa; Z Ali-Khan
Journal:  Br J Exp Pathol       Date:  1988-02

7.  The role of fibronectin in the development of experimental amyloidosis. Evidence of immunohistochemical codistribution and binding property with serum amyloid protein A.

Authors:  E Kawahara; M Shiroo; I Nakanishi; S Migita
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

8.  Metabolism of senile amyloid precursor and amyloidogenesis. Age-related acceleration of apolipoprotein A-II clearance in the senescence accelerated mouse.

Authors:  H Naiki; K Higuchi; T Yonezu; M Hosokawa; T Takeda
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

9.  Identification in milk of a serum amyloid A peptide chemoattractant for B lymphoblasts.

Authors:  Berardo de Jesus Rodriguez; Claire Chevaleyre; Gwénaële Henry; Daniel Mollé; Isabelle Virlogeux-Payant; Mustapha Berri; François Boulay; Joëlle Léonil; François Meurens; Henri Salmon
Journal:  BMC Immunol       Date:  2009-01-23       Impact factor: 3.615

10.  Isolation and characterization of senile amyloid--related antigenic substance (SASSAM) from mouse serum. Apo SASSAM is a low molecular weight apoprotein of high density lipoprotein.

Authors:  K Higuchi; A Matsumura; K Hashimoto; A Honma; S Takeshita; M Hosokawa; K Yasuhira; T Takeda
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.